Case Report
Twelve months of emicizumab prophylaxis in a severe hemophilia A man with inhibitor who failed immune tolerance induction: effectiveness, economic, and safety outcomes
Lido
3916
Vezesque se leu este artigo
1306
Total PDF
2610
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 6 | 29 | 6 | 35 |
| 2025 5 | 61 | 15 | 76 |
| 2025 4 | 64 | 10 | 74 |
| 2025 3 | 68 | 14 | 82 |
| 2025 2 | 46 | 21 | 67 |
| 2025 1 | 45 | 15 | 60 |
| 2024 12 | 39 | 22 | 61 |
| 2024 11 | 39 | 26 | 65 |
| 2024 10 | 37 | 24 | 61 |
| 2024 9 | 67 | 38 | 105 |
| 2024 8 | 53 | 35 | 88 |
| 2024 7 | 76 | 25 | 101 |
| 2024 6 | 72 | 38 | 110 |
| 2024 5 | 54 | 34 | 88 |
| 2024 4 | 58 | 18 | 76 |
| 2024 3 | 77 | 22 | 99 |
| 2024 2 | 63 | 23 | 86 |
| 2024 1 | 58 | 22 | 80 |
| 2023 12 | 54 | 28 | 82 |
| 2023 11 | 71 | 37 | 108 |
| 2023 10 | 53 | 31 | 84 |
| 2023 9 | 48 | 48 | 96 |
| 2023 8 | 80 | 17 | 97 |
| 2023 7 | 70 | 9 | 79 |
| 2023 6 | 67 | 30 | 97 |
| 2023 5 | 77 | 27 | 104 |
| 2023 4 | 57 | 25 | 82 |
| 2023 3 | 91 | 32 | 123 |
| 2023 2 | 87 | 31 | 118 |
| 2023 1 | 45 | 11 | 56 |
| 2022 12 | 37 | 15 | 52 |
| 2022 11 | 62 | 20 | 82 |
| 2022 10 | 39 | 21 | 60 |
| 2022 9 | 46 | 26 | 72 |
| 2022 8 | 25 | 23 | 48 |
| 2022 7 | 29 | 26 | 55 |
| 2022 6 | 42 | 30 | 72 |
| 2022 5 | 41 | 28 | 69 |
| 2022 4 | 90 | 27 | 117 |
| 2022 3 | 45 | 29 | 74 |
| 2022 2 | 42 | 26 | 68 |
| 2021 1 | 60 | 32 | 92 |
| 2021 12 | 36 | 35 | 71 |
| 2021 11 | 42 | 30 | 72 |
| 2021 10 | 40 | 54 | 94 |
| 2021 9 | 28 | 31 | 59 |
| 2021 8 | 41 | 26 | 67 |
| 2021 7 | 27 | 24 | 51 |
| 2021 6 | 14 | 27 | 41 |
| 2021 5 | 18 | 42 | 60 |
Mostrar tudo
